Pyroptosis-boosting nanoadjuvants enable effective in situ cancer vaccination

Subjects Cancer immunotherapyCell death and immune response We developed a nanoadjuvant platform that targets early endosome membranes in tumour cells, triggering their pyroptosis and the release of pyroptosomes, which act as an in situ vaccine against the tumour. In preclinical cancer models featuring multiple metastases, this nanoplatform enabled spatiotemporal induction of robust immune responses, resulting in systemic tumour eradication and long-lasting antitumour immunity. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this articlePurchase on SpringerLinkInstant access to the full article PDF.USD 39.95Prices may be subject to local taxes which are calculated during checkout Fig. 1: SPEN-boosted in situ vaccination via pyroptosomes. ReferencesGong, N. Q. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607–625 (2024). A review article on advanced delivery technologies for enhancing in situ cancer vaccines.Article CAS PubMed Google Scholar Meier, P. et al. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer 24, 299–315 (2024). A comprehensive review on the mechanisms and antitumour therapeutic potential of immunogenic cell death.Article CAS PubMed Google Scholar Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020). This paper reports the activation of antitumour immunity by gasdermin E-mediated cancer cell pyroptosis.Article CAS PubMed PubMed Central Google Scholar Chen, B. et al. A pyroptosis nanotuner for cancer therapy. Nat. Nanotechnol. 17, 788–798 (2022). This paper reports cancer-specific and tunable pyroptosis induced by ultra-pH-sensitive technology through endosome maturation.Article CAS PubMed Google Scholar Download referencesAdditional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.This is a summary of: Chen, B. et al. In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy. Nat. Mater. https://doi.org/10.1038/s41563-026-02506-9 (2026).Rights and permissionsReprints and permissionsAbout this articleCite this article Pyroptosis-boosting nanoadjuvants enable effective in situ cancer vaccination. Nat. Mater. (2026). https://doi.org/10.1038/s41563-026-02505-wDownload citationPublished: 13 March 2026Version of record: 13 March 2026DOI: https://doi.org/10.1038/s41563-026-02505-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy Binlong ChenFangjie WanYiguang Wang Nature Materials Article 03 Mar 2026